Michael Depenbusch, MD
Ophthalmology · Chandler, AZNPI 1003897794
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.3% of the total across 77 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by Bausch & Lomb, A Division Of Bausch Health US, LLC at 27.0% of the total. Reporting peaked in 2019 at $587 and has fallen 88.4% since, to $68 in 2025. That places this record below the midpoint for ophthalmology clinicians in AZ, where the typical reported total is $1,526.
Across 77 payments — averaging $20.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb, A Division Of Bausch Health US, LLC$433
- Bausch & Lomb Americas Inc.$322
- Hoffmann-la Roche Limited$136
- AbbVie$115
- Alcon$114
- Rxsight Inc$71
- plus $413 from 13 others
Across 313 payments — averaging $7195.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$573K
- Bausch & Lomb Americas Inc.$527K
- Dompe Farmaceutici S.p.a.$451K
- Oyster Point Pharma, Inc.$290K
- Glaukos Corporation$226K
- Kala Pharmaceuticals, Inc.$107K
- plus $78K from 5 others
What the payments were for
- Speaking & faculty fees$584%
- Food & beverage$1,53095%
- Education$181%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 26 | $433 |
| Bausch & Lomb Americas Inc. | 12 | $322 |
| Hoffmann-la Roche Limited | 1 | $136 |
| AbbVie | 7 | $115 |
| Alcon | 6 | $114 |
| Rxsight Inc | 4 | $71 |
| Glaukos Corporation | 3 | $68 |
| Dutch Ophthalmic, USA | 2 | $52 |
| Sun Pharmaceutical Industries Inc. | 2 | $41 |
| Shire North American Group Inc | 2 | $41 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $37 |
| Kala Pharmaceuticals, Inc. | 2 | $36 |
| Omeros Corporation | 2 | $33 |
| Notal Vision, Inc. | 1 | $32 |
| Carl Zeiss Meditec USA, Inc. | 1 | $17 |
| Amgen | 1 | $17 |
| Thea Pharma Inc. | 1 | $16 |
| Novartis | 1 | $13 |
| Akorn Operating Company LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- STELLARIS$149
- enVista MX60 IOL$149
How this compares
$1,605 in reported general payments places this provider in the 50th percentile of 310 ophthalmology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 20 | $25,815 |
| Cyclosporine | 22 | $12,299 |
| LumiganBimatoprost | 26 | $9,929 |
| Prednisolone Acetate | 331 | $8,675 |
| XiidraLifitegrast | 11 | $8,673 |
| VyzultaLatanoprostene Bunod | 18 | $8,525 |
| TobradexTobramycin/Dexamethasone | 27 | $7,146 |
| Latanoprost | 516 | $7,006 |
| Travoprost | 29 | $5,812 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 32 | $5,657 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 14 | $5,102 |
| Brimonidine Tartrate | 125 | $4,907 |
| Ketorolac Tromethamine | 268 | $4,857 |
| Ciprofloxacin Hcl | 238 | $2,481 |
| Timolol Maleate | 106 | $1,424 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $115 | $35,74546 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $322 | $17,19929 claims |
| AlconSimbrinza | $114 | $5,10214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 310 ophthalmology providers in Arizona.
Other ophthalmology in Chandler
- Warren HillMesa$1.1M
- Mark BarakatScottsdale$794K
- Anne ZakiSun City West$518K
- Pravin DugelPhoenix$176K
- Derek KunimotoMesa$138K
- Shamil PatelGlendale$116K
- Yuri McKeeMesa$100K
- Nishi ShahPhoenix$92K
- Lisa MihoraPeoria$91K
- George ReissGlendale$73K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.